{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:52:41Z","timestamp":1788479561390,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"am","delay-in-days":684,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bmcl.2022.128724","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T21:17:08Z","timestamp":1649452628000},"page":"128724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Efficiency of bis-amidate phosphonate prodrugs"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1701-0753","authenticated-orcid":false,"given":"Nicholas A.","family":"Lentini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4912-0375","authenticated-orcid":false,"given":"Xueting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-4250","authenticated-orcid":false,"given":"Megan A.","family":"Schladetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hung Christine","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Wiemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wiemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128724_b0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","article-title":"The relationship between the chemistry and biological activity of the bisphosphonates","volume":"49","author":"Ebetino","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bmcl.2022.128724_b0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/128_2014_561","article-title":"Prodrugs of phosphonates and phosphates: crossing the membrane barrier","volume":"360","author":"Wiemer","year":"2015","journal-title":"Top Curr Chem"},{"key":"10.1016\/j.bmcl.2022.128724_b0015","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1016\/j.ejmech.2011.05.040","article-title":"A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities","volume":"46","author":"Jansa","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128724_b0020","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cmdc.201500183","article-title":"Bisamidate prodrugs of 2-substituted 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA, adefovir) as selective inhibitors of adenylate cyclase toxin from Bordetella pertussis","volume":"10","author":"Cesnek","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2022.128724_b0025","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/2326-6066.CIR-15-0190","article-title":"T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition","volume":"3","author":"Houot","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.bmcl.2022.128724_b0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","article-title":"Translating gammadelta (gammadelta) T cells and their receptors into cancer cell therapies","volume":"19","author":"Sebestyen","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2022.128724_b0035","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.it.2021.06.002","article-title":"Targeting butyrophilins for cancer immunotherapy","volume":"42","author":"Rigau","year":"2021","journal-title":"Trends Immunol"},{"key":"10.1016\/j.bmcl.2022.128724_b0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41577-020-00452-4","article-title":"\u03b3\u03b4 T cells in tissue physiology and surveillance","volume":"21","author":"Ribot","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmcl.2022.128724_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645131","article-title":"V\u03b39V\u03b42 T cells concurrently kill cancer cells and cross-present tumor antigens","volume":"12","author":"Holmen Olofsson","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2022.128724_b0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0192","article-title":"Characterization of ascites- and tumor-infiltrating \u03b3\u03b4 T cells reveals distinct repertoires and a beneficial role in ovarian cancer","volume":"13","author":"Foord","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmcl.2022.128724_b0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.2006.00479.x","article-title":"Nonpeptide antigens, presentation mechanisms, and immunological memory of human V\u03b39V\u03b42 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens","volume":"215","author":"Morita","year":"2007","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bmcl.2022.128724_b0060","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","article-title":"Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gamma delta T-cell subset","volume":"120","author":"Harly","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2022.128724_b0065","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/eji.201444712","article-title":"V gamma 9V delta 2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6","volume":"44","author":"Riano","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bmcl.2022.128724_b0070","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/cmdc.202000198","article-title":"Structure-activity relationships of butyrophilin 3 ligands","volume":"15","author":"Wiemer","year":"2020","journal-title":"ChemMedChem"},{"issue":"8","key":"10.1016\/j.bmcl.2022.128724_b0075","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41423-021-00720-w","article-title":"Self-activation of V\u03b39V\u03b42 T cells by exogenous phosphoantigens involves TCR and butyrophilins","volume":"18","author":"Laplagne","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.bmcl.2022.128724_b0080","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/jm701101g","article-title":"Synthesis and biological activity of phosphonate analogues and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate","volume":"51","author":"Boedec","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128724_b0085","article-title":"Ligand-induced interactions between butyrophilin 2A1 and 3A1 internal domains in the HMBPP receptor complex. Cell","author":"Hsiao","year":"2022","journal-title":"Chem Biol"},{"key":"10.1016\/j.bmcl.2022.128724_b0090","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1172\/JCI132489","article-title":"\u03b39\u03b42T cell diversity and the receptor interface with tumor cells","volume":"130","author":"Vyborova","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmcl.2022.128724_b0095","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.immuni.2014.03.003","article-title":"The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human V\u03b39V\u03b42 T cells","volume":"40","author":"Sandstrom","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.bmcl.2022.128724_b0100","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.chembiol.2014.06.006","article-title":"Synthesis of a phosphoantigen prodrug that potently activates V\u03b39V\u03b42 T-lymphocytes","volume":"21","author":"Hsiao","year":"2014","journal-title":"Chem Biol"},{"key":"10.1016\/j.bmcl.2022.128724_b0105","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.4049\/jimmunol.1401064","article-title":"Activation of human \u03b3\u03b4 T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin","volume":"194","author":"Rhodes","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2022.128724_b0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4049\/jimmunol.1501833","article-title":"HMBPP analog prodrugs bypass energy-dependent uptake to promote efficient BTN3A1-mediated malignant cell lysis by V gamma 9V delta 2 T lymphocyte effectors","volume":"197","author":"Kilcollins","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2022.128724_b0115","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bcp.2018.10.035","article-title":"A power law function describes the time- and dose-dependency of V\u03b39V\u03b42 T cell activation by phosphoantigens","volume":"158","author":"Hsiao","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2022.128724_b0120","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1021\/acsptsci.0c00076","article-title":"Metabolic efficacy of phosphate prodrugs and the remdesivir paradigm","volume":"3","author":"Wiemer","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.bmcl.2022.128724_b0125","doi-asserted-by":"crossref","first-page":"8658","DOI":"10.1021\/acs.jmedchem.8b00655","article-title":"Phosphonamidate prodrugs of a butyrophilin ligand display plasma stability and potent V\u03b39 V\u03b42 T cell stimulation","volume":"61","author":"Lentini","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128724_b0130","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1021\/acsmedchemlett.9b00153","article-title":"Synthesis and bioactivity of the alanyl phosphonamidate stereoisomers derived from a butyrophilin ligand","volume":"10","author":"Lentini","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128724_b0135","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/acsmedchemlett.7b00245","article-title":"Mixed aryl phosphonate prodrugs of a butyrophilin ligand","volume":"8","author":"Foust","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128724_b0140","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/cmdc.201900344","article-title":"Stability and efficiency of mixed aryl phosphonate prodrugs","volume":"14","author":"Foust","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2022.128724_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115666","article-title":"Potent double prodrug forms of synthetic phosphoantigens","volume":"28","author":"Harmon","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2022.128724_b0150","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1128\/AAC.00103-09","article-title":"GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions","volume":"53","author":"Wolfgang","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2022.128724_b0155","doi-asserted-by":"crossref","first-page":"8632","DOI":"10.1021\/jm2011673","article-title":"Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents","volume":"54","author":"McGuigan","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128724_b0160","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.bmcl.2006.10.021","article-title":"Design and synthesis of novel bis(L-amino acid) ester prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) with improved anti-HBV activity","volume":"17","author":"Fu","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128724_b0165","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2012.01.013","article-title":"Synthesis, anti-HBV activity and renal cell toxicity evaluation of mixed phosphonate prodrugs of adefovir","volume":"49","author":"Fu","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128724_b0170","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.138","article-title":"Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917","volume":"3","author":"Kubota","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.bmcl.2022.128724_b0175","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1128\/AAC.01685-13","article-title":"Amidate prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine as inhibitors of adenylate cyclase toxin from Bordetella pertussis","volume":"58","author":"\u0160m\u00eddkov\u00e1","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2022.128724_b0180","article-title":"Halogen-dance-based synthesis of phosphonomethoxyethyl (PME) substituted 2-aminothiazoles as potent inhibitors of bacterial adenylate cyclases","author":"\u010cesnek","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2022.128724_b0185","doi-asserted-by":"crossref","first-page":"15491","DOI":"10.1021\/ja074871l","article-title":"Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes","volume":"129","author":"Dang","year":"2007","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2022.128724_b0190","doi-asserted-by":"crossref","DOI":"10.1039\/C5OB00281H","article-title":"Applying the prodrug strategy to alpha-phosphonocarboxylate inhibitors of Rab GGTase - synthesis and stability studies","author":"Joachimiak","year":"2015","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmcl.2022.128724_b0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ab.2012.09.001","article-title":"Quantitative determination of isopentenyl diphosphate in cultured mammalian cells","volume":"433","author":"Tong","year":"2013","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bmcl.2022.128724_b0200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1021\/acsmedchemlett.1c00408","article-title":"Synthesis and metabolism of BTN3A1 ligands: studies on diene modifications to the phosphoantigen scaffold","volume":"13","author":"Harmon","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128724_b0205","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1021\/acsmedchemlett.0c00586","article-title":"Synthesis and metabolism of BTN3A1 ligands: studies on modifications of the allylic alcohol","volume":"12","author":"Lentini","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128724_b0210","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/mol.108.045526","article-title":"Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases","volume":"74","author":"Birkus","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmcl.2022.128724_b0215","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1021\/jm000302b","article-title":"Activation mechanisms of nucleoside phosphoramidate prodrugs","volume":"43","author":"Freel Meyers","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128724_b0220","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1211\/jpp.60.5.0002","article-title":"Pharmaceutical and pharmacological importance of peptide transporters","volume":"60","author":"Brandsch","year":"2008","journal-title":"J Pharm Pharmacol"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22002001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22002001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:44:47Z","timestamp":1760773487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22002001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":44,"alternative-id":["S0960894X22002001"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128724","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficiency of bis-amidate phosphonate prodrugs","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128724"}}